EGFR and neoplasm: More interestingly, cftDNA can also detect the changes in tumor heterogeneity due to clonal evolution during a specific treatment line: studies have shown that some patients acquire resistance to a first-line anti-EGFR treatment but undergo a re-sensitization after some subsequent EGFR-blockade-free lines, rendering them eligible, again, for anti-EGFR challenge [85].